Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsStrides pharma

    Strides Pharma

    Jump to

    • Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y

    • Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y

    • Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y

    • Strides Pharma Consolidated June 2025 Net Sales at Rs 1,119.74 crore, up 2.96% Y-o-Y

    • Strides Pharma Consolidated March 2025 Net Sales at Rs 1,190.39 crore, up 9.81% Y-o-Y

    • Strides Pharma Consolidated March 2025 Net Sales at Rs 1,190.39 crore, up 9.81% Y-o-Y

    • Strides Pharma Standalone March 2025 Net Sales at Rs 555.96 crore, down 9.99% Y-o-Y

    • Strides Pharma Consolidated December 2024 Net Sales at Rs 1,153.67 crore, up 11.18% Y-o-Y

    • Strides Pharma Standalone December 2024 Net Sales at Rs 550.92 crore, up 5.94% Y-o-Y

    • Strides gets NCLT nod for specialty pharma CDMO OneSource, listing in due course

      This integration is backed by an equity commitment of Rs 801 crore ($95 million) from a clutch of investors, valuing the company at a pre-money equity valuation of $1.65 billion, positions OneSource for "robust growth", said Strides.

    • Strides Pharma Consolidated September 2024 Net Sales at Rs 1,201.11 crore, up 20.18% Y-o-Y

    • Strides Pharma Standalone September 2024 Net Sales at Rs 609.96 crore, up 12.89% Y-o-Y

    • Strides Pharma stock gains 2% after associate firm secures Rs 800-crore fund commitments

      The company said share subscription agreements are being executed at a pre-money equity value of $1.65 billion

    • Aditya Birla Sun Life Mutual Fund decreases stake in Strides Pharma to 3.49%

      Strides Pharma is known for its presence in the pharmaceutical space. It's share price has delivered 106.94 percent returns in 2024 so far.

    • Strides Pharma Consolidated June 2024 Net Sales at Rs 1,087.51 crore, up 16.94% Y-o-Y

    • Strides Pharma Standalone June 2024 Net Sales at Rs 554.75 crore, up 16.71% Y-o-Y

    • Strides Pharma Standalone March 2024 Net Sales at Rs 617.63 crore, up 9.6% Y-o-Y

    • Strides Pharma Consolidated March 2024 Net Sales at Rs 1,084.04 crore, up 9.9% Y-o-Y

    • Strides Pharma Consolidated March 2024 Net Sales at Rs 1,084.04 crore, up 9.9% Y-o-Y

    • Strides Pharma Consolidated December 2023 Net Sales at Rs 1,037.67 crore, up 19.98% Y-o-Y

    • Strides Pharma Standalone December 2023 Net Sales at Rs 520.02 crore, up 34.54% Y-o-Y

    • Strides Pharma Consolidated September 2023 Net Sales at Rs 999.43 crore, up 11.41% Y-o-Y

    • Strides Pharma Standalone September 2023 Net Sales at Rs 540.29 crore, up 12.27% Y-o-Y

    • Strides Pharma to sell its Singapore manufacturing facility for $15 million

      Additionally, as part of the transaction, Rxilient Biohub will assume the long-term lease obligation associated with the manufacturing site from Strides

    • Strides Pharma falls 5% from 52-week highs on spin off of CDMO

      Strides Pharma shareholders would receive 1 share of OneSource for every 2 shares of Strides in the swap ratio of 1:2

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347